{"entity":{"id":"nct07005154","kind":"trial","name":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer","aka":[],"tldr":"A phase 2 trial of Prednisone, Abiraterone acetate in prostate cancer, run by Astellas Pharma Global Development, Inc., now recruiting.","summary":"A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer is a phase 2 interventional study registered as NCT07005154 by Astellas Pharma Global Development, Inc., with 218 participants planned, started 2025-08-19 and due to reach its primary completion in 2032-05-31. Interventions recorded: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone. Conditions listed: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07005154","url":"https://clinicaltrials.gov/study/NCT07005154"}],"tags":["ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["prednisone","abiraterone"],"companies":["astellas"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07005154","phase":"2","setting":"A Phase 2, Open-label, Multi-cohort Study to Assess the Efficacy and Safety of ASP5541 in Participants With Advanced Prostate Cancer","sponsor":"Astellas Pharma Global Development, Inc.","enrolled":218,"outcomes":[]},"route":"/trials/nct07005154/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"}]}}